Woeltjen Matthias Michael, Niehoff Julius Henning, Roggel Ruth, Michael Arwed Elias, Gerdes Berthold, Surov Alexey, Borggrefe Jan, Kroeger Jan Robert
Department of Radiology, Neuroradiology and Nuclear Medicine, Johannes Wesling University Hospital, Ruhr University Bochum, Bochum, Germany.
Department of Radiology, Neuroradiology and Nuclear Medicine, Johannes Wesling University Hospital, Ruhr University Bochum, Bochum, Germany.
Eur J Radiol. 2024 Apr;173:111374. doi: 10.1016/j.ejrad.2024.111374. Epub 2024 Feb 18.
The aim of the study was to identify differences in the tumor conspicuity of pancreatic adenocarcinomas in different monoenergetic or polyenergetic reconstructions and contrast phases in photon-counting CT (PCCT).
34 patients were retrospectively enrolled in this study. Quantitative image analysis was performed with region of interest (ROI) measurements in different monoenergetic levels ranging from 40 up to 70 keV (5-point steps) and polyenergetic series. Tumor-parenchyma attenuation differences and contrast-to-noise-ratio (CNR) were calculated. A qualitative image analysis was accomplished by 4 radiologists using a 5-point Likert scale (1 = "not recognizable" up to 5 = "easy recognizable"). Differences between groups were evaluated for statistical significance using the Friedman test and in case of significant differences pair-wise post-hoc testing with Bonferroni correction was applied.
Tumor-parenchyma attenuation difference was significantly different between the different image reconstructions for both arterial- and portal-venous-phase-images (p < 0.001). Tumor-parenchyma attenuation difference was significantly higher on arterial-phase-images at mono40keV compared to polyenergetic images (p < 0.001) and mono55keV images or higher (p < 0.001). For portal-venous-phase-images tumor-parenchyma attenuation difference was significantly higher on mono40keV images compared to polyenergetic images (p < 0.001) and mono50keV images (p = 0.03) or higher (p < 0.001). The same trend was seen for CNR. Tumor conspicuity was rated best on mono40keV images with 4.3 ± 0.9 for arterial-phase-images and 4.3 ± 1.1 for portal-venous-phase-images. In contrast, overall image quality was rated best on polyenergetic-images with 4.8 ± 0.5 for arterial-phase-images and 4.7 ± 0.6 for portal-venous-phase-images.
Low keV virtual monoenergetic images significantly improve the tumor conspicuity of pancreatic adenocarcinomas in PCCT based on quantitative and qualitative results. On the other hand, readers prefer polyenergetic images for overall image quality.
本研究旨在确定在光子计数CT(PCCT)中,不同单能或多能重建以及对比剂注射期相下胰腺腺癌的肿瘤显影差异。
本研究回顾性纳入了34例患者。在40至70 keV(步长为5 keV)的不同单能水平以及多能序列下,通过感兴趣区(ROI)测量进行定量图像分析。计算肿瘤-实质衰减差异和对比噪声比(CNR)。4名放射科医生采用5分李克特量表(1 =“不可识别”至5 =“易于识别”)完成定性图像分析。使用Friedman检验评估组间差异的统计学意义,若存在显著差异,则应用Bonferroni校正进行两两事后检验。
在动脉期和门静脉期图像的不同图像重建之间,肿瘤-实质衰减差异均有显著差异(p < 0.001)。与多能图像(p < 0.001)以及单能55 keV及以上图像(p < 0.001)相比,单能40 keV动脉期图像的肿瘤-实质衰减差异显著更高。对于门静脉期图像,与多能图像(p < 0.001)以及单能50 keV图像(p = 0.03)及以上图像(p < 0.001)相比,单能40 keV图像的肿瘤-实质衰减差异显著更高。CNR也呈现相同趋势。肿瘤显影在单能40 keV图像上评分最佳,动脉期图像评分为4.3±0.9,门静脉期图像评分为4.3±1.1。相比之下,多能图像的整体图像质量评分最佳,动脉期图像评分为4.8±0.5,门静脉期图像评分为4.7±0.6。
基于定量和定性结果,低keV虚拟单能图像显著提高了PCCT中胰腺腺癌的肿瘤显影。另一方面,读者更倾向于多能图像的整体图像质量。